Efficacy of Anti-TNF-α Therapy for the Treatment of Non-infectious Uveitis: A Retrospective Study of 21 Patients

REFERENCES

• Wakefield D, Chang JH. Epidemiology of uveitis. Int Ophthalmol Clin. 2005;45:1–13.
   PubMedGoogle Scholar
• Jabs DA, Rosenbaum JT. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol. 2001;131:679.
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72:3666–3670.
   PubMed Web of Science ®Google Scholar
• Nakamura S, Yamakawa T, Sugita M, et al. The role of tumor necrosis factor-alpha in the induction of experimental autoimmune uveoretinitis in mice. Invest Ophthalmol Vis Sci. 1994;35:3884–3889.
   PubMed Web of Science ®Google Scholar
• Santos Lacomba M, Marcos Martín C, Gallardo Galera JM, et al. Aqueous humor and serum tumor necrosis factor-alpha in clinical uveitis. Ophthalmic Res. 2001;33:251–255.
   PubMed Web of Science ®Google Scholar
• Robertson M, Liversidge J, Forrester JV, et al. Neutralizing tumor necrosis factor-alpha activity suppresses activation of infiltrating macrophages in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci. 2003;44:3034–3041.
   PubMed Web of Science ®Google Scholar
• Murphy CC, Ayliffe WH, Booth A, et al. Tumor necrosis factor alpha blockade with infliximab for refractory uveitis and scleritis. Ophthalmology. 2004;111:352–356.
   PubMed Web of Science ®Google Scholar
• Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol. 2005;140:509–516.
   PubMed Web of Science ®Google Scholar
• Martel JN, Esterberg E, Nagpal A, et al. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012;20:18–26.
   PubMed Web of Science ®Google Scholar
• Kam KW, Tam LS, Tam MKP, et al. Infliximab in the treatment of refractory ocular inflammatory diseases. Asia Pac J Ophthalmol. 2015;4:19–24.
   PubMed Web of Science ®Google Scholar
• Kruh JN, Yang P, Suelves AM, et al. Infliximab for the treatment of refractory noninfectious uveitis: a study of 88 patients with long-term follow-up. Ophthalmology. 2014;121:358–364.
   PubMed Web of Science ®Google Scholar
• Lopez-Gonzalez R, Loza E, Jover JA, et al. Treatment of refractory posterior uveitis with infliximab: a 7-year follow-up study. Scand J Rheumatol. 2009;38:58–62.
   PubMed Web of Science ®Google Scholar
• Brezin AP, Kestelyn P, Van Calster J, et al. Adalimumab in patients with active, noninfectious uveitis using high-dose corticosteroids. Arthritis Rheumatol. 2015;67(suppl 10).
   Google Scholar
• Díaz-Llopis M, Salom D, Garcia-de-Vicuña C, et al. Treatment of refractory uveitis with adalimumab: a prospective multicenter study of 131 patients. Ophthalmology. 2012;119:1575–1581.
   PubMed Web of Science ®Google Scholar
• Dobner BC, Max R, Becker MD, et al. A three-centre experience with adalimumab for the treatment of non-infectious uveitis. Br J Ophthalmol. 2013;97:134–138.
   PubMed Web of Science ®Google Scholar
• Vallet H, Seve P, Biard L, et al. Infliximab versus Adalimumab in the treatment of refractory inflammatory uveitis: a multicenter study from the French uveitis network. Arthritis Rheumatol. 2016;68:1522–1530.
   PubMed Web of Science ®Google Scholar
• Morris DS, Gavin MP, Sturrock RD. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet’s disease. Adv Exp Med Biol. 2003;528:557–559.
   PubMed Web of Science ®Google Scholar
• Tugal-Tutkun I, Mudun A, Urgancioglu M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet’s disease: an open-label trial. Arthritis Rheum. 2005;52:2478–2484.
   PubMed Web of Science ®Google Scholar
• Niccoli L, Nannini C, Benucci M, et al. Long-term efficacy of infliximab in refractory posterior uveitis of Behcet’s disease: a 24-month follow-up study. Rheumatology (Oxford). 2007;46:1161–1164.
   PubMed Web of Science ®Google Scholar
• Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Behçet’s disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics. 2012;6:5–12.
   PubMedGoogle Scholar
• Perra D, Alba MA, Callejas JL, et al. Adalimumab for the treatment of Behçet’s disease: experience in 19 patients. Rheumatology (Oxford). 2012;51:1825–1831.
   Google Scholar
• Calvo-Río V, Blanco R, Beltrán E, et al. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet’s disease: a 1-year follow-up study of 124 patients. Rheumatology (Oxford). 2014;53:2223–2231.
   PubMed Web of Science ®Google Scholar
• Takeuchi M, Kezuka T, Sugita S, et al. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet’s disease: a multicenter study. Ophthalmology. 2014;121:1877–1884.
   Google Scholar
• Okada AA, Goto H, Ohno S, et al. Ocular Behçet’s Disease Research Group Of Japan. Multicenter study of infliximab for refractory uveoretinitis in Behçet disease. Arch Ophthalmol. 2012;130:592–598.
   PubMed Web of Science ®Google Scholar
• Interlandi E, Leccese P, Olivieri I, et al. Adalimumab for treatment of severe Behçet’s uveitis: a retrospective long-term follow-up study. Clin Exp Rheumatol. 2014;32:S58–S62.
   PubMed Web of Science ®Google Scholar
• Sfikakis PP, Markomichelakis N, Alpsoy E, et al. Anti-TNF therapy in the management of Behçet’s disease—review and basis for recommendations. Rheumatology. 2007;46:736–741.
   PubMed Web of Science ®Google Scholar
• Levy-Clarke G, Jabs DA, Read RW, et al. Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology. 2014;121:785–796.
   PubMed Web of Science ®Google Scholar
• Artornsombudh P, Gevorgyan O, Payal A, et al. Infliximab treatment of patients with birdshot retinochoroidopathy. Ophthalmology. 2013;120:588–592.
   PubMed Web of Science ®Google Scholar
• Menezo V, Taylor SR. Birdshot uveitis: current and emerging treatment options. Clin Ophthalmol. 2014;8:73–81.
   PubMedGoogle Scholar
• Riancho-Zarrabeitia L, Calvo-Río V, Blanco R, et al. Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: Multicenter study of 17 patients. Semin Arthritis Rheum. 2015;45:361–368.
   PubMed Web of Science ®Google Scholar
• Lindstedt EW, Baarsma GS, Kuijpers RW, et al. Anti-TNF-alpha therapy for sight threatening uveitis. Br J Ophthalmol. 2005;89:533–536.
   PubMed Web of Science ®Google Scholar
• Hangai M, He S, Hoffmann S, et al. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol. 2006;171:45–56.
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol. 2004;138:648–650.
   PubMed Web of Science ®Google Scholar
• Schaap-Fogler M, Amer R, Friling R, et al. Anti-TNF-α agents for refractory cystoid macular edema associated with noninfectious uveitis. Graefes Arch Clin Exp Ophthalmol. 2014;252:633–640.
   PubMed Web of Science ®Google Scholar
• Durez P, Malghem J, Toukap AN, et al. Treatment of early rheumatoid arthritis: A randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. Arthritis Rheum. 2007;56:3919–3927.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, Azathioprine, or Combination Therapy for Crohn’s Disease. N Engl J Med. 2010;362:1383–1395.
   PubMed Web of Science ®Google Scholar
• Dhingra N, Morgan J, Dick AD. Switching biologic agents for uveitis. Eye (Lond). 2009;23:1868–1870.
   Google Scholar
• Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275–2285.
   PubMed Web of Science ®Google Scholar
• Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. Rheumatology (Oxford). 2006;45:1294–1297.
   PubMed Web of Science ®Google Scholar
• Mercieca C, Vella N, Borg AA. Demyelination during anti-TNFα therapy for ankylosing spondylitis. Mod Rheumatol. 2012;22:303–307.
   PubMed Web of Science ®Google Scholar
• Berghen N, Teuwen L-A, Westhovens R, et al. Malignancies and anti-TNF therapy in rheumatoid arthritis: a single-center observational cohort study. Clin Rheumatol. 2015;34:1687–1695.
   Google Scholar
• Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol. 2005;123:903–912.
   PubMed Web of Science ®Google Scholar
• Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol. 2009;127:819–822.
   PubMed Web of Science ®Google Scholar
• Chen L, Gordon LK. Ocular manifestations of multiple sclerosis. Curr Opin Ophthalmol. 2005;16:315–320.
   PubMedGoogle Scholar
• Cordero-Coma M, Sobrin L. Anti-tumor necrosis factor-α therapy in uveitis. Surv Ophthalmol. 2015;60:575–589.
   PubMed Web of Science ®Google Scholar